InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.510 0 (0%)+
Announcement
Release
2 Jul 2026 10:11AM
Price at Release
$0.510
Full Release
download
Summary
Cyclopharm Limited reported a record revenue growth of 11% for the first half of FY26, primarily driven by the expansion of their Technegas® installations in the US. The company's functional lung imaging product, Technegas®, is recognized in newly approved international guidelines, which have broadened to include the US, European, and ANZ markets. Despite delays in these guidelines impacting short-term installation targets in the US, the company remains confident in reaching medium-term goals of 2,000 installations. Technegas® revenue in the US increased by approximately 73% year-over-year, contributing to a total global revenue of around $17.1 million. Cyclopharm aims to leverage AI-driven analysis to expand clinical applications of Technegas® across various respiratory conditions. The company reported a closing cash balance of $12.2 million as of June 2026 and anticipates reduced cash consumption as more installations become revenue-generating.
Key Points
  • Record 1H FY26 revenue of $17.1 million, up 11% from 1H FY25.
  • US Technegas® revenue grew by 73% year-on-year.
  • International guidelines now include US, European, and ANZ markets.
  • Delayed US installation targets shifted to post-December 2026.
  • Medium-term target of 2,000 US installations remains.
  • AI-driven expansion of Technegas® clinical applications.
  • Closing cash balance of $12.2 million as of June 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.